Case Details
- Citation: [2017] SGHC 322
- Case Title: Novartis (Singapore) Pte Ltd v Bristol-Myers Squibb Pharma Co
- Court: High Court of the Republic of Singapore
- Date of Decision: 20 December 2017
- Judge: George Wei J
- Coram: George Wei J
- Case Number: Originating Summons No 1002 of 2016
- Procedural Context: Originating summons for rectification of the patents register arising in connection with High Court Suit No 1146 of 2015
- Plaintiff/Applicant: Novartis (Singapore) Pte Ltd (“Novartis”)
- Defendant/Respondent: Bristol-Myers Squibb Pharma Company (“Bristol-Myers”)
- Counsel for Applicant: Suhaimi bin Lazim, Chow Jian Hong and Yan Chongshuo (Mirandah Law LLP)
- Counsel for Respondent: Alvin Lim Jun Hao and Desmond Chew Tse Sern (Dentons Rodyk & Davidson LLP)
- Legal Area: Patents and inventions — Rectification of register
- Statutes Referenced (as reflected in the judgment extract): Patents Act (Cap 221, 2005 Rev Ed); Medicines Act (Cap 176, 1985 Rev Ed); Patent Cooperation Treaty (PCT); Paris Convention; Stockholm Act; Patents Rules (Cap 221, R 1, 2007 Rev Ed)
- Key Statutory Provisions Mentioned: Patents Act s 44 (rectification); Patents Act s 17 (priority); Patents Act ss 85–87 (international applications treated as national applications); Medicines Act s 12A(3)(a) (notice mechanism); PCT Art 8 and PCT Regulations r 4.1(b); Paris Convention Art 4D(1); Patents Rules r 25(1) (unity of invention)
- Patents at Issue: Five Singapore patents: SG 76157, SG 77853, SG 134977, SG 111980, SG 111981
- Product Licence Application: EFAVIRENZ SANDOZ FILM COATED TABLET 600MG
- Judgment Length (as provided): 33 pages, 18,897 words
- Cases Cited (as provided): [2017] SGHC 322
Summary
This case arose out of a pharmaceutical patent dispute connected to Singapore’s Medicines Act regime for product licences. Novartis, after applying to the Health Sciences Authority for a product licence for a specified efavirenz product, served notices on the patent proprietor, Bristol-Myers, under the statutory notice mechanism. Bristol-Myers responded by commencing infringement proceedings in the High Court and, crucially for the present application, asserted a priority date of 11 June 1988 derived from an earlier US patent application.
Novartis challenged Bristol-Myers’ entitlement to rely on that priority date, arguing that the document cited in support of the claimed priority related to a completely different invention. After Novartis filed its defence, Bristol-Myers investigated and discovered that an error had occurred during prosecution: the wrong earlier US patent application number had been entered in the relevant forms. Bristol-Myers then sought and obtained corrections from the Registrar of Patents. Novartis brought the present originating summons to reverse those corrections, seeking rectification of the patents register under s 44 of the Patents Act.
In substance, the High Court had to decide whether the Registrar’s corrections should stand, and whether the patent proprietor could rely on the corrected priority claim for the purposes of the infringement litigation. The judgment provides guidance on the approach to rectification of patent registers in Singapore, particularly where the dispute turns on the correction of priority-related information and the impact of such corrections on substantive patent rights.
What Were the Facts of This Case?
Bristol-Myers was the proprietor of five Singapore patents under the Patents Act. The patents broadly concerned pharmaceutical inventions. The patents were identified as SG 76157, SG 77853, SG 134977, SG 111980, and SG 111981. Novartis, as a generic or follow-on manufacturer, sought regulatory approval for a product that fell within the scope of the Medicines Act product licence framework.
On 30 October 2013, Novartis applied to the Health Sciences Authority for a product licence for “EFAVIRENZ SANDOZ FILM COATED TABLET 600MG”. After the application was made, Novartis served notices on Bristol-Myers on or about 24 September 2015 pursuant to s 12A(3)(a) of the Medicines Act. This notice mechanism is designed to alert patent proprietors to impending regulatory steps that may lead to acts capable of infringing patent rights.
Following receipt of the notice, Bristol-Myers commenced High Court Suit No 1146 of 2015. In that suit, Bristol-Myers sought declarations that the acts for which the product licence was sought would infringe the Singapore patents, and an injunction to prevent those acts. In its pleadings, Bristol-Myers claimed a priority date of 11 June 1988. That priority date was said to derive from an earlier US patent application for the same (or a similar) invention.
Novartis’ defence contested the priority claim. Novartis argued that Bristol-Myers was not entitled to rely on the claimed priority date because the document cited in support of that priority related to a different invention, unrelated to the inventions described in the Singapore patents. This was not merely a technical pleading point; priority affects the assessment of novelty and inventive step by fixing the relevant “state of the art” date under the Patents Act. If the priority date was wrong, the validity and scope of the patents could be materially affected.
After Novartis filed its defence, Bristol-Myers investigated the prosecution history and discovered an error in the application process. The wrong earlier US patent application number had been entered in the relevant forms. Bristol-Myers therefore applied to the Registrar of Patents for correction of the entries in the patents register so that the correct US patent application number would be reflected in support of the claimed priority date. The Registrar granted the requests and made the corrections. Novartis disagreed and commenced the present originating summons for rectification of the register under s 44 of the Patents Act, contending that the Registrar should not have allowed the corrections.
What Were the Key Legal Issues?
The primary issue was whether the patents register should be rectified to reverse the Registrar’s corrections. This required the court to consider the legal basis and limits of rectification under s 44, and the circumstances in which an error in priority-related information may be corrected. The dispute also necessarily engaged the relationship between the register and substantive patent rights: corrections to the register can affect what priority is legally treated as claimed, which in turn can affect validity and infringement analysis.
A second issue concerned the effect of the correction on the priority claim itself. Novartis’ argument was that the cited document supported a different invention, undermining Bristol-Myers’ entitlement to the claimed priority date. Bristol-Myers’ response was that the error was clerical/procedural in nature—an incorrect US application number was entered—rather than a substantive misidentification of the invention. The court therefore had to assess whether the corrected priority claim reflected the true intended priority basis and whether it could be relied upon.
Finally, the case raised contextual issues about how Singapore patent law treats international applications and priority claims. The judgment included an overview of the Patents Act framework, including priority under s 17, and the PCT mechanism for international applications designating Singapore. While these were not the direct “dispositive” issues, they formed the doctrinal backdrop for understanding how priority information is recorded and later corrected.
How Did the Court Analyse the Issues?
The court began by setting out the statutory and institutional framework relevant to priority and registration. Singapore’s Patents Act is based on the UK Patents Act 1977 and, historically, on the European Patent Convention 1973. The court emphasised that the substantive requirements for patentability—novelty, inventive step, and industrial applicability—are assessed by reference to the state of the art as it existed at the priority date of the claimed invention. This makes priority claims central to both validity and infringement proceedings.
Under s 17 of the Patents Act, the default priority date is the filing date of the application, but an earlier date may be claimed under s 17(2) where there is an earlier application made within the preceding 12 months. The court also explained that the earlier application may be from a “convention country” and that a declaration must be made within the prescribed period. These provisions show that priority is not an abstract concept; it is tied to specific earlier filings and to formal declarations made during prosecution.
The judgment then addressed the PCT system and how international applications are treated in Singapore. Under ss 85–87 of the Patents Act, an international application designating Singapore and accorded a filing date under the PCT is treated as if it were an application under the Patents Act. Further, declarations of priority made under the PCT are treated as having been made under s 17(2). This matters because the priority information in the register is often derived from PCT filings and the associated priority claims contained in the PCT request. The court’s explanation underscores that priority information is recorded through formal mechanisms, and errors can arise in the transcription of those priority details into the Singapore record.
Against this doctrinal background, the court turned to the dispute’s factual core: Bristol-Myers had claimed priority based on an earlier US patent application number, but the wrong number had been entered in the relevant forms. The court accepted that the facts were largely undisputed, and the disagreement centred on whether the Registrar’s corrections were properly made and should be reversed. In other words, the question was not whether an error occurred, but whether the correction was legally permissible and whether it accurately reflected the intended priority basis.
Although the extract provided does not include the full reasoning on the rectification standard, the structure of the judgment indicates that the court approached rectification as a matter of correcting the register to reflect the true position, while balancing the interests of certainty in the register against the need to correct genuine mistakes. The court also had to consider the practical effect of rectification on the ongoing infringement litigation: if the corrected priority claim stood, Bristol-Myers could rely on the earlier priority date; if the corrections were reversed, Novartis’ challenge to priority could potentially undermine the patents’ validity or narrow their enforceable scope.
In assessing whether the Registrar should have allowed the corrections, the court necessarily considered what the register should contain and how priority claims are supported. The court’s analysis would have required attention to the nature of the error (for example, whether it was a clerical mistake in the application number rather than a substantive change in the invention), the evidential basis for the correction, and whether the correction would prejudice third parties or undermine the integrity of the registration system. The judgment’s emphasis on the first-time nature of the issue in Singapore suggests that the court was careful to articulate principles that would guide future rectification disputes.
What Was the Outcome?
The High Court dismissed Novartis’ originating summons seeking rectification to reverse the Registrar’s corrections. The practical effect was that the corrected entries in the patents register—reflecting the correct earlier US patent application number supporting the claimed priority date—remained in place.
As a result, Bristol-Myers was able to continue relying on the corrected priority basis in the connected infringement proceedings. For Novartis, the decision meant that its priority-based defence could not be advanced by attacking the register corrections through rectification; instead, any further challenge would have to be directed at substantive issues such as claim construction, infringement, and validity on the corrected priority framework.
Why Does This Case Matter?
This decision is significant for patent practitioners because it clarifies how Singapore courts may treat rectification of the patents register where priority-related information has been corrected by the Registrar. Priority claims are often the hinge on which novelty and inventive step analysis turns. Where a mistake occurs in the recorded priority basis, the ability to correct the register—and the circumstances in which such correction will be upheld—can materially affect litigation strategy and outcomes.
From a procedural standpoint, the case illustrates the interaction between regulatory processes under the Medicines Act and patent enforcement. The statutory notice mechanism can trigger infringement proceedings, and those proceedings may depend on priority claims that are recorded in the register. Rectification disputes therefore become a critical parallel track that can determine what priority date is available for the infringement and validity analysis.
Substantively, the judgment also reinforces that Singapore’s patent system is closely connected to international filing mechanisms under the PCT and to convention priority principles. Practitioners should therefore ensure that priority details submitted through international applications are accurately reflected in the Singapore record, and should be prepared to address rectification issues if errors are discovered. The case is also a reminder that while the register promotes certainty, it is not immutable: genuine mistakes may be corrected, and courts will scrutinise whether the correction reflects the intended legal position.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), including:
- Section 17 (priority)
- Section 44 (rectification of the register)
- Sections 85–87 (international applications treated as applications under the Patents Act; priority treated as made under s 17(2))
- Patents Rules (Cap 221, R 1, 2007 Rev Ed), including:
- Rule 25(1) (unity of invention)
- Medicines Act (Cap 176, 1985 Rev Ed), including:
- Section 12A(3)(a) (notice mechanism for product licence applications)
- Patent Cooperation Treaty (PCT), including:
- Article 8 (priority claims)
- PCT Regulations (entered into force 1 July 2017), including:
- Rule 4.1(b) and related provisions on priority claim content
- Paris Convention for the Protection of Industrial Property (1883), including:
- Article 4D(1) (requirements to specify date and country for priority)
- Stockholm Act (of the Paris Convention) (as referenced in the judgment extract)
Cases Cited
- [2017] SGHC 322
Source Documents
This article analyses [2017] SGHC 322 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.